Recombinant Human IGF-BP5
Catalog Number : 100-05
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.
Above 98% as determined by SDS-PAGE Analysis.
The ED50 was determined by its ability to inhibit IGF-II induced proliferation of MCF-7 is ≤ 0.3 μg/ml in the presence of 15 ng/ml of human IGF-II.
MLGSFVHCE PCDEKALSM CPPSPLGCE LVKEPGCGC CMTCALAEG QSCGVYTER CAQGLRCLP RQDEEKPLH ALLHGRGVC LNEKSYREQ VKIERDSRE HEEPTTSEM AEETYSPKI FRPKHTRIS ELKAEAVKK DRRKKLTQS KFVGGAENT AHPRIISAP EMRQESEQG PCRRHMEAS LQELKASPR MVPRAVYLP NCDRKGFYK RKQCKPSRG RKRGICWCV DKYGMKLPG MEYVDGDFQ CHTFDSSNV S
|Research Interest:||Apoptosis, Cancer, Proliferation and Cell Cycle, Metabolic Regulation and Diabetes|
|Protein Cross Reactivity:||NULL|